Advances in immunosuppression for renal transplantation

Nat Rev Nephrol. 2010 Mar;6(3):160-7. doi: 10.1038/nrneph.2009.233. Epub 2010 Feb 2.


The development of immunosuppressants with minimal adverse and nephrotoxic effects is important to improve outcomes, such as acute and chronic antibody-mediated rejection, after organ transplantation. In addition, the application of expanded criteria for donors and transplantation in immunized patients necessitates the development of new therapies. Drug development over the past 10 years has generally been disappointing, but several new promising compounds have been or are being developed to prevent acute and chronic transplant rejection. In this Review, we report on several compounds that have been developed to remove allogenic T cells and/or to inhibit T-cell activation. We also discuss compounds that interfere with antibody-mediated rejection.

Publication types

  • Review

MeSH terms

  • Animals
  • Female
  • Forecasting
  • Graft Rejection
  • Graft Survival
  • Haplorhini
  • Humans
  • Immunosuppression Therapy / methods
  • Immunosuppression Therapy / trends*
  • Immunosuppressive Agents / pharmacology
  • Immunosuppressive Agents / therapeutic use*
  • Kidney Transplantation / adverse effects
  • Kidney Transplantation / immunology*
  • Kidney Transplantation / methods
  • Male
  • Prognosis
  • Risk Assessment
  • Safety Management
  • Survival Analysis
  • Transplantation Immunology / drug effects*
  • Transplantation Immunology / physiology
  • Transplantation Tolerance / drug effects
  • Transplantation Tolerance / immunology
  • Treatment Outcome


  • Immunosuppressive Agents